• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > GenitoUrinary Tract Disorders

• Effects of platelet-activating factor on nitrergic transmission in rabbit corpus cavernosum.
• Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
• A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
• Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
• In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats.
• Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.
• Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists.
• A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
• Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke?
• A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.
• Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
• Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
• Interleukin-6- and tumour necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cells and its involvement in the growth of endometriosis.
• A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.
• Differential effects of activation of peripheral and spinal tachykinin neurokinin(3) receptors on the micturition reflex in rats.
• DPI-221 [4-((alpha-s)-alpha-((2s,5r)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: a novel nonpeptide delta receptor agonist producing increased micturition interval in normal rats.
• High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
• Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.
• Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.
• Which anticholinergic drug for overactive bladder symptoms in adults.
• Early molecular-level changes in rat bladder wall tissue following spinal cord injury.
• Action potential refractory period in ureter smooth muscle is set by Ca sparks and BK channels.
• Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget.
• Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis.
• Individual differences in male rat ejaculatory behaviour: searching for models to study ejaculation disorders.
• Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study.
• Sildenafil improves quality of life in men with heart failure and erectile dysfunction.
• Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.
• Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds.
• Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
• Increased basal phosphorylation of detrusor smooth muscle myosin in alloxan-induced diabetic rabbit is mediated by upregulation of Rho-kinase beta and CPI-17.
• Bladder storage and emptying disorder frequencies in hemorrhagic and ischemic stroke patients with bladder dysfunction.
• Lack of soluble TNF-receptors in women with recurrent spontaneous abortion and possibility for its correction.
• Submucosal injection of poly(lactic-co-glycolic acid) microspheres in rabbit bladder as a potential treatment for urinary incontinence and vesicoureteral reflux: preliminary results.
• Non-steroidal anti-inflammatory drugs for pain in women with endometriosis.
• Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.
• The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease.
• Correlation between ejaculatory and erectile dysfunction.
• Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment.
• Mixed incontinence: the misclassification of patients and limitations of clinical trials.
• Intravesical therapy for overactive bladder.
• Erectile dysfunction as a marker for vascular disease.
• Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man.
• Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management.
• Venlafaxine-induced urinary incontinence resolved after switching to sertraline.
• Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
• Deficits in sexual and aggressive behaviors in Cnga2 mutant mice.
• CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.
• Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
• Mode of delivery and severe stress incontinence. a cross-sectional study among 2,625 perimenopausal women.
• Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model.
• Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis.
• Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor.
• Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia.
• Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy.
• Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.
• BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
• Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
• Role for pituitary adenylate cyclase activating polypeptide in cystitis-induced plasticity of micturition reflexes.
• The direct cost of stress urinary incontinence among women in a Medicaid population.
• The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase.
• Synthesis and pharmacological evaluation of new progesterone esters as 5alpha-reductase inhibitors.
• Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats.
• Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.
• Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.
• Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
• The role of Ni(2+)-sensitive T-type Ca(2+) channels in the regulation of spontaneous excitation in detrusor smooth muscles of the guinea-pig bladder.
• Using a treatment satisfaction measure in an early trial to inform the evaluation of a new treatment for benign prostatic hyperplasia.
• Injection of skeletal muscle-derived cells into the penis improves erectile function.
• Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction.
• Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury.
• Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction.
• Investigation of early protein changes in the urinary bladder following partial bladder outlet obstruction by proteomic approach.
• Nitric oxide inhibition of the proliferation of ovarian endometriotic stromal cells in vitro.
• Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
• Contractile mechanisms in diabetes-related erectile dysfunction.
• Rho-kinase and RGS-containing RhoGEFs as molecular targets for the treatment of erectile dysfunction.
• Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model.
• Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline.
• Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis.
• Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study.
• Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
• The prevalence of erectile dysfunction in men visiting outpatient clinics.
• Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction.
• Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
• Prevalence of bladder dysfunction in Parkinsons disease.
• Colonic irritation in the rat sensitizes urinary bladder afferents to mechanical and chemical stimuli: an afferent origin of pelvic organ cross-sensitization.
• Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
• Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.
• Central muscarinic receptor subtypes regulating voiding in rats.
• Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex.
• Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
• The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey.
• Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.
• Erectile dysfunction and subsequent cardiovascular disease.
• Cytochrome P450 epoxygenases provide a novel mechanism for penile erection.
• Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
• Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.
• Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study.
• Comorbidity between social phobia and premature ejaculation: study on 242 males affected by sexual disorders.
• Intracavernous injection of prostaglandin E1 is effective in patients with erectile dysfunction not responding to phosphodiseterase 5 inhibitors.
• Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle.
• Effects of imatinib mesylate (Glivec) as a c-kit tyrosine kinase inhibitor in the guinea-pig urinary bladder.
• Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.
• Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.
• Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.
• Alterations in purinergic and cholinergic components of contractile responses of isolated detrusor contraction in a rat model of partial bladder outlet obstruction.
• Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity.
• Sildenafil extends survival and graft function in a large animal lung transplantation model.
• Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
• Erectile dysfunction and statin treatment in high cardiovascular risk patients.
• Synthesis and pharmacological evaluation of some N-arylsulfonyl-N-methyl-N'-(2,2-dimethyl-2H-1-benzopyran-4-yl)ureas structurally related to cromakalim.
• Risk factors for urinary incontinence among middle-aged women.
• The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
• Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate.
• Multicenter phase III trial studying trospium chloride in patients with overactive bladder.
• The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition.
• Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction.
• The functional effects of a c-kit tyrosine inhibitor on guinea-pig and human detrusor.
• Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review.
• Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation.
• Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
• Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding.
• Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
• Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia.
• Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States.
• Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study.
• Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder.
• Expression of smoothelin in the normal and the overactive human bladder.
• Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland.
• Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
• Inhibitory mechanism of monensin on high K+-induced contraction in guniea-pig urinary bladder.
• Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2-adrenoceptor agonist and a selective uterine relaxant.
• Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.
• Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy.
• Induced endometriosis in the baboon (Papio anubis) increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria.
• Pathophysiology of overactive bladder.
• Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
• Disruptive effects of overactive bladder and urge urinary incontinence in younger women.
• Pharmacologic management of overactive bladder: practical options for the primary care physician.
• Management of overactive bladder and urge urinary incontinence in the elderly patient.
• Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs.
• Suppression of bladder reflex activity in chronic spinal cord injured cats by activation of serotonin 5-HT1A receptors.
• Alternatively spliced neuronal nitric oxide synthase mediates penile erection.
• Furosemide use and hospitalization for benign prostatic hyperplasia.
• Hypoactive sexual desire disorder in menopausal women: a survey of Western European women.
• Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers.
• Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
• Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology.
• Assessment of sexual dysfunction in patients with benign prostatic hyperplasia.
• Major depression in female urinary incontinence.
• Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic peptide associated with obesity and hyperleptinemia.
• Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial.
• The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats.
• Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004).
• Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon.
• Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells.
• [Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists]
• [Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)]
• [Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats--study of the selectivity for lower urinary tract]
• [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]
• [Duration of action of silodosin (KMD-3213) against phenylephrine-induced increase in intraurethral pressure in rats]
• JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
• Safety and tolerability of duloxetine in women with stress urinary incontinence.
• Effects of tamsulosin on resting urethral pressure and arterial blood pressure in anaesthetized female dogs.
• Safety and efficacy of tamsulosin in the treatment of painful ejaculation: a randomized, double-blind, placebo-controlled study.
• Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction.
• Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study.
• An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
• SV2 is the protein receptor for botulinum neurotoxin A.
• The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
• How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study.
• Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study.
• Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey.
• Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial.
• The potential and promise of using botulinum toxin in the prostate gland.
• Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling.
• Molecular properties and preclinical pharmacology of JNJ-1250132, a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro.
• Selective beta-adrenoceptor agonists, calcium antagonists and potassium channel openers as a possible medical treatment of the overactive bladder and urge incontinence.
• Characterization of intracavernous pressure increase induced by Ym348, a novel 5-HT2C receptor agonist, in anesthetized rats.
• Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle.
• BPH: epidemiology and comorbidities.
• Treatment and pharmacologic management of BPH in the context of common comorbidities.
• BPH: costs and treatment outcomes.
• Pharmacological management of women with mixed urinary incontinence.
• Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study.
• Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
• Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo.
• The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice.
• 5-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists.
• Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design.
• Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction.
• Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries.
• Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial.
• Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up.
• A novel approach to the treatment of benign prostatic hyperplasia.
• Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
• Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
• Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity.
• Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction.
• Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
• Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
• Prostaglandin receptors are mediators of vascular function in endometrial pathologies.
• Participation of endogenous endothelin and ET(A) receptor in premicturition contractions in rats with bladder outlet obstruction.
• Leflunomide--an immunomodulator--induces regression of endometrial explants in a rat model of endometriosis.
• Design and synthesis of selective alpha1B adrenoceptor antagonists.
• A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy.
• Endothelin-A-receptor antagonist LU 302146 inhibits electrostimulation-induced bladder contractions in vivo.
• Contractile mechanisms coupled to TRPA1 receptor activation in rat urinary bladder.
• Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study.
• Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
• Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.
• Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002.
• Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
• Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia.
• Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training.
• Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.
• A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
• Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
• Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
• Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial.
• Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.
• IkappaB kinase 2 inhibition corrects defective nitrergic erectile mechanisms in diabetic mouse corpus cavernosum.
• New progesterone receptor antagonists: phosphorus-containing 11beta-aryl-substituted steroids.
• Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study.
• Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
• Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
• "Ejaculatory disorders and alpha1-adrenoceptor antagonists therapy: clinical and experimental researches".
• Role of estrogens in inflammatory response: expression of estrogen receptors in peritoneal fluid macrophages from endometriosis.
• Gabapentin treatment of neurogenic overactive bladder.
• The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.
• Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
• Prevalence of erectile dysfunction in Asian populations: a meta-analysis.
• The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.
• Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.
• Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.
• The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking.
• Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder.
• Diagnosis and management of endometriosis.
• Effect of regular phosphodiesterase type 5 inhibition in hypertension.
• The Sexual Arousal and Desire Inventory (SADI): a multidimensional scale to assess subjective sexual arousal and desire.
• Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction.
• Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
• Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey.
• Cardiovascular risk factors determine erectile and arterial function response to sildenafil.
• Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
• Efficacy of sildenafil citrate in treatment of erectile dysfunction: impact of associated premature ejaculation and low desire.
• An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer.
• Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
• Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
• Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.
• Actions of ZD0947, a novel ATP-sensitive K+ channel opener, on membrane currents in human detrusor myocytes.
• Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat.
• The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder.
• Finasteride induced depression: a prospective study.
• New pyrimido[5,4-b]indoles and [1]benzothieno[3,2-d]pyrimidines: high affinity ligands for the alpha(1)-adrenoceptor subtypes.
• The role of angiotensin II in stress urinary incontinence: A rat model.
• Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
• Effects of ovariectomy and oestrogen replacement on the function and expression of Rho-kinase in rat bladder smooth muscle.
• Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder.
• Chiral selective effects of doxazosin enantiomers on blood pressure and urinary bladder pressure in anesthetized rats.
• Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
• Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.
• PIP3EA and PD-168077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain.
• Characterization and restoration of altered inhibitory and excitatory control of micturition reflex in experimental autoimmune encephalomyelitis in rats.
• Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.
• Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.
• Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study.
• Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction.
• Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase.
• Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
• Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations).
• Are there differences between women with urge predominant and stress predominant mixed urinary incontinence?
• Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators.
• Female sexual dysfunction in essential hypertension: a common problem being uncovered.
• Design and synthesis of rho kinase inhibitors (III).
• Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
• Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
• Partial bladder outlet obstruction selectively abolishes protein kinase C induced contraction of rabbit detrusor smooth muscle.
• Novel technique for monitoring micturition and sexual function in male rats using telemetry.
• Lack of central nitric oxide triggers erectile dysfunction in diabetes.
• Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
• Effect of a statin on an in vitro model of endometriosis.
• Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.
• A gap junction blocker inhibits isolated whole bladder activity in normal rats and rats with partial bladder outlet obstruction.
• Antidepressant-induced inhibition of genital vascular responses is reversed by vardenafil in female rabbits.
• Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model.
• Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naïve men with ED and their partners.
• Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
• Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.
• Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED.
• Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
• Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
• Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
• Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.
• Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation.
• Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ).
• The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
• hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial.
• Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
• Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial.
• Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
• Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction.
• Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
• Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction.
• Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
• Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor.
• BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
• Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction.
• Valsartan treatment reverses erectile dysfunction in diabetic rats.
• Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
• 1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonists.
• A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human.
• Ex vivo biomechanical properties of the female urethra in a rat model of birth trauma.
• Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold.
• Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis.
• Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
• Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
• Autoantibody-mediated bladder dysfunction in type 1 diabetes.
• Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
• The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study.
• Bidirectional relationship between depression and erectile dysfunction.
• Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
• Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats.
• Tadalafil for treatment of erectile dysfunction in men on antidepressants.
• Vardenafil restores erectile function to normal range in men with erectile dysfunction.
• Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
• Transdermal testosterone gel prn application for hypoactive sexual desire disorder in premenopausal women: a controlled pilot study of the effects on the arizona sexual experiences scale for females and sexual function questionnaire.
• High-dose atorvastatin causes regression of endometriotic implants: a rat model.
• The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract.
• Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
• Clozapine for the treatment of neurogenic bladder.
• 1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective alpha-1a/1d adrenergic receptor ligands.
• Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
• The efficacy of duloxetine in the treatment of premature ejaculation.
• Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction.
• Botulinum toxin B is not an effective treatment of refractory overactive bladder.
• Prevalence and risk factors for erectile dysfunction in the US.
• Changes in T-type calcium channel and its subtypes in overactive detrusor of the rats with partial bladder outflow obstruction.
• Parameters of bladder function in pre-, peri-, and postmenopausal continent women without detrusor overactivity.
• Taurine ameliorates stress-induced degeneration of the urinary bladder.
• Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care.
• Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
• A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
• Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.
• Finasteride versus dutasteride: a real-world economic evaluation.
• Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
• RhoA/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate.
• Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction.
• The role of the prostacyclin receptor antagonist RO3244019 in treating neurogenic detrusor overactivity after spinal cord injury in rats.
• Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
• Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.
• Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
• Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
• Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
• Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha.
• Sildenafil improves walk distance in idiopathic pulmonary fibrosis.
• FK1706 enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat.
• Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing.
• Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes.
• Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
• Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction.
• Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
• Proteomic analysis of rat penile tissue in a model of erectile dysfunction after radical prostatectomy.
• Antisense and Short Hairpin RNA (shRNA) Constructs Targeting PIN (Protein Inhibitor of NOS) Ameliorate Aging-Related Erectile Dysfunction in the Rat.
• An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice.
• Characterization of a novel ATP-sensitive K(+) channel opener, A-251179, on urinary bladder relaxation and cystometric parameters.
• Antisense Oligodeoxynucleotides for Estrogen Receptor-beta and alpha Attenuate Estradiol's Modulation of Affective and Sexual Behavior, Respectively.
• Comparison of prevalence between self-reported erectile dysfunction and erectile dysfunction as defined by five-item International Index of Erectile Function in Taiwanese men older than 40 years.
• Rho-kinase inhibition suppresses potassium chloride-induced bladder hyperactivity in a rat model.
• Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone.
• Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence.
• Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task.
• Long-term results of three different minimally invasive therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: Comparison at a single institute.
• Can sildenafil treat primary premature ejaculation? A prospective clinical study.
• Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.
• Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
• Antioxidant Treatment Associated with Sildenafil Reduces Monocyte Activation and Markers of Endothelial Damage in Patients with Diabetic Erectile Dysfunction: A Double-Blind, Placebo-Controlled Study.
• Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.
• A Rational Combination Pharmacotherapy in Men with Erectile Dysfunction who Initially Failed to Oral Sildenafil Citrate Alone: A Pilot Study.
• An alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate glutamate-receptor antagonist can inhibit premicturition contractions in rats with bladder outlet obstruction.
• Treatment of overactive bladder: Selective use of anticholinergic agents with low drug-drug interaction potential. .
• The prevalence of erectile dysfunction among hypertensive and prehypertensive men aged 25-40 years.
• PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: A prospective, randomized, placebo- and drug-controlled study.
• Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: Immunocytochemistry, autoradiography and behavioral studies.
• Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial.
• Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
• Dysfunctional voiding confirmed by transdermal perineal electromyography, and its effective treatment with baclofen in women with lower urinary tract symptoms: a randomized double-blind placebo-controlled crossover trial.
• Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.
• A novel mouse model for assessment of male sexual function.
• (Phenylpiperidinyl)cyclohexylsulfonamides: Development of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
• A-272651, a nonpeptidic blocker of large-conductance Ca(2+)-activated K(+) channels, modulates bladder smooth muscle contractility and neuronal action potentials.
• Estrogen receptor {beta}-deficient female mice develop a bladder phenotype resembling human interstitial cystitis.
• Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis.
• The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
• Analysis of the efficacy and safety of sildenafil citrate in the geriatric population.
• Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
• 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
• Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists.
• Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
• Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire.
• Absorption, Metabolism and Excretion of [14C]Imidafenacin, a New Compound for Treatment of Overactive Bladder, Following Oral Administration to Healthy Male Subjects.
• Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury.
• Validation of the Overactive Bladder Symptom Score.
• Long-Term Tolerability of Tolterodine Extended Release in Children 5-11 Years of Age: Results from a 12-Month, Open-Label Study.
• Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg.
• Pharmacological validation of a model of cystitis pain in the mouse.
• Thiosemicarbazones of Formyl Benzoic Acids as Novel Potent Inhibitors of Estrone Sulfatase.
• Relevance of anti-reactive oxygen species activity to anti-inflammatory activity of components of Eviprostat((R)), a phytotherapeutic agent for benign prostatic hyperplasia.
• Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
• Sildenafil Promotes Ischemia-Induced Angiogenesis Through a PKG-Dependent Pathway.
• Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
• Tungstate administration improves the sexual and reproductive function in female rats with streptozotocin-induced diabetes.
• An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat.
• The utility of sildenafil citrate for infertile men with sexual dysfunction: a pilot study.
• Prulifloxacin versus Levofloxacin in the Treatment of Chronic Bacterial Prostatitis: a Prospective, Randomized, Double-Blind Trial.
• Effects of BAY 41-2272 on smooth muscle tone, soluble guanylyl cyclase activity and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal and endothelial NOS null mice.
• Differentially expressed gene networks in cultured smooth muscle cells from normal and neuropathic bladder.
• Prediction of alpha(1)-Adrenoceptor Occupancy in the Human Prostate from Plasma Concentrations of Silodosin, Tamsulosin and Terazosin to Treat Urinary Obstruction in Benign Prostatic Hyperplasia.
• alpha(1)-Adrenoceptors are required for normal male sexual function.
• Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility.
• Demonstration of 5-HT(3) receptor function and expression in the mouse bladder.
• Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
• Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study.
• GW427353 (solabegron) a novel selective {beta}3 adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.
• A mouse model of hypercholesterolemia-induced erectile dysfunction.
• Bladder afferent sensitivity in wildtype and TRPV1 knockout mice.
• Synthesis and optimization of novel and selective muscarinic M(3) receptor antagonists.
• Changes of M(3)-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocin-induced diabetic rats.
• Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX-1.
• Did Patients With Interstitial Cystitis Who Failed to Respond to Initial Treatment With Bacillus Calmette-Guerin or Placebo in a Randomized Clinical Trial Benefit From a Second Course of Open Label Bacillus Calmette-Guerin?
• Once Daily Trospium Chloride is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial.
• Activation of Urothelial-TRPV4 by 4{alpha}PDD contributes to altered bladder reflexes in the rat.
• Botulinum toxin injections for adults with overactive bladder syndrome.
• Design, Synthesis, and in Vivo SAR of a Novel Series of Pyrazolines as Potent Selective Androgen Receptor Modulators.
• Montelukast reduces ischaemia/reperfusion-induced bladder dysfunction and oxidant damage in the rat.
• Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: A single dose, 4 weeks, double-blind, randomized, placebo controlled trial.
• Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells.
• Gene transfer of the K(ATP) channel restores age-related erectile dysfunction in rats.
• Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia.
• Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice.
• Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder.
• Mouse model of erectile dysfunction due to diet-induced diabetes mellitus.
• Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats.
• Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure.
• Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
• 5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.
• Effect of recombinant human endostatin on endometriosis in mice.
• Darifenacin treatment of patients >/= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
• The effect of oxybutynin on structural changes of the obstructed guinea pig bladder.
• Beneficial effects of suplatast tosilate (IPD-1151T) in a rat cystitis model induced by intravesical hydrochloric acid.
• Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
• Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan.
• Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data.
• Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in korean healthy volunteers.
• Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity.
• The effect of sildenafil citrate and pentoxifylline combined treatment in the management of erectile dysfunction.
• Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
• Botulinum Toxin A Detrusor Injections in Patients with Neurogenic Detrusor Overactivity Significantly Decrease the Incidence of Symptomatic Urinary Tract Infections.
• Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.
• A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
• Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
• Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB(1) and vanilloid VR(1) receptors.
• Effect of letrozole on urinary bladder function in the female rabbit.
• Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
• Changes of gap junctional cell-cell communication in overactive detrusor in the rats.
• The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia.
• Vardenafil Improves Urodynamic Parameters in Men With Spinal Cord Injury: Results From a Single Dose, Pilot Study.
• Effect of Recombinant Human Keratinocyte Growth Factor (rHuKGF, Palifermin) on Radiation-Induced Mouse Urinary Bladder Dysfunction.
• Aldose Reductase Inhibitor ONO-2235 Restores the Alterations of Bladder Nerve Growth Factor and Neurotrophin Receptor p75 Genetic Expression in Streptozotocin Induced Diabetic Rats.
• Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.
• Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
• The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure.
• Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?
• Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.
• Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
• Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
• Aminocyclohexylsulfonamides: Discovery of metabolically stable alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
• Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
• Potent oxindole based human beta(3) adrenergic receptor agonists.
• Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
• Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
• Infusions of 3alpha,5alpha-THP to the VTA enhance exploratory, anti-anxiety, social, and sexual behavior and increase levels of 3alpha,5alpha-THP in midbrain, hippocampus, diencephalon, and cortex of female rats.
• Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease.
• Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome.
• Does Tolterodine Extended Release Affect the Bladder Electrical Perception Threshold? A Placebo Controlled, Double-Blind Study With 4 and 8 mg in Healthy Volunteers.
• Danazol for pelvic pain associated with endometriosis.
• Effects of the Selective Prostacyclin Receptor Antagonist RO3244019 on the Micturition Reflex in Rats.
• An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study.
• Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding.
• Premature Ejaculation: Results from a Five-Country European Observational Study.
• Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist.
• Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
• Acute Effects of Nicotine on Physiological and Subjective Sexual Arousal in Nonsmoking Men: A Randomized, Double-Blind, Placebo-Controlled Trial.
• Structure-Activity Studies of Novel Cyanoguanidine ATP-Sensitive Potassium Channel Openers for the Treatment of Overactive Bladder.
• Structural analogue of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.
• Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis.
• Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
• Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
• Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
• Effect of hyperforin-enriched extract on pro-ejaculatory effect of 8-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats.
• cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil.
• The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study.
• Tolterodine does not affect memory assessed by passive-avoidance response test in mice.
• The discovery of GSK221149A: A potent and selective oxytocin antagonist.
• Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT(2C) receptor agonists.
• Synthesis and evaluation of a gamma-lactam as a highly selective EP(2) and EP(4) receptor agonist.
• Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.
• The age distribution, rates, and types of surgery for stress urinary incontinence in the USA.
• The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers.
• (Phenylpiperazinyl)cyclohexylureas: Discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
• Effects of Continuous versus Cyclic Oral Contraception: A Randomized Controlled Trial.
• Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon alpha-2a as Monotherapy.
• Inhibitory effects of nicorandil, a K(ATP) channel opener and a nitric oxide donor, on overactive bladder in animal models.
• The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
• Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
• Comparative studies of ZD0947, a novel ATP-sensitive K(+) channel opener, on guinea pig detrusor and aortic smooth muscles.
• In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
• Synthesis and biological activity of novel peptide mimetics as melanocortin receptor agonists.
• In vivo study on the effects of alpha(1)-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs.
• The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study.
• Effect of Saw Palmetto Soft Gel Capsule on Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized Trial in Shanghai, China.
• Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
• Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT(2C) receptor agonists.
• Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.
• Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction.
• Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury.
• The broad-spectrum chemokine inhibitor NR58-3.14.3 suppresses the implantation and survival of human endometrial implants in the nude mice endometriosis model.
• Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms in Men (January).
• Lycopene Inhibits Disease Progression in Patients with Benign Prostate Hyperplasia.
• Tadalafil (cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial.
• High-Dose Terazosin Therapy (5mg) in Korean Patients with Lower Urinary Tract Symptoms with or without Concomitant Hypertension: A Prospective, Open-Label Study.
• Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
• Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: A placebo-controlled, double-blind, randomized trial.
• Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors.
• A gonadotropin-releasing hormone agonist versus a continuous oral contraceptive pill in the treatment of bladder endometriosis.
• Evaluation of the Safety and Efficacy of Bremelanotide, a Melanocortin Receptor Agonist, in Female Subjects with Arousal Disorder: A Double-Blind Placebo-Controlled, Fixed Dose, Randomized Study.
• Role of Chloride Channels in the Regulation of Corpus Cavernosum Tone: A Potential Therapeutic Target for Erectile Dysfunction.
• Phosphorylation Increases Affinity of the Phosphodiesterase-5 Catalytic Site for Tadalafil.
• Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms.
• 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor-1{alpha} and Suppresses Growth of Lesions in a Mouse Model of Endometriosis.
• Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study.
• Efficacy of a Novel Device for Assessment of Autonomic Sensory Function in the Rat Bladder.
• Expression of alpha(1)-Adrenoceptor Subtype mRNA as a Predictor of the Efficacy of Subtype Selective alpha(1)-Adrenoceptor Antagonists in the Management of Benign Prostatic Hyperplasia.
• Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.
• Use of the NuvaRing(R) hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus.
• Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
• Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study.
• Gamendazole, an Orally Active Indazole Carboxylic Acid Male Contraceptive Agent, Targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and Stimulates Il1a Transcription in Rat Sertoli Cells.
• Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.
• Combination of Alfuzosin and Tadalafil Exerts In Vitro an Additive Relaxant Effect on Human Corpus Cavernosum.
• The Efficacy and Safety of Udenafil, a New Selective Phosphodiesterase Type 5 Inhibitor, in Patients with Erectile Dysfunction.
• Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine.
• Synthesis and screening of a cyclic peptide library: Discovery of small-molecule ligands against human prolactin receptor.
• Effective Treatment of Neurogenic Detrusor Dysfunction by Combined High-Dosed Antimuscarinics without Increased Side-Effects.
• 11-(Pyridinylphenyl)steroids-A new class of mixed-profile progesterone agonists/antagonists.
• Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
• Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial.
• The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
• Monoaryl-Substituted Salicylaldoximes as Ligands for Estrogen Receptor beta.
• Rapid Antimicrobial Susceptibility Determination of Uropathogens in Clinical Urine Specimens Using ATP Bioluminescence.
• Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model.
• A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium.
• A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
• Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil.
• The Influence of Cardiovascular Disease on Health Related Quality of Life in Men With Prostate Cancer: A 4-Year Followup Study.
• Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
• Altered expression of calcium-activated K and Cl channels in detrusor overactivity of rats with partial bladder outlet obstruction.
• Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat.
• Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
• Focal adhesion kinase expression in ovarian endometriosis.
• Design and synthesis of 3-arylpyrrolidine-2-carboxamide derivatives as melanocortin-4 receptor ligands.
• Interleukin-12 but not interleukin-18 is associated with severe endometriosis.
• Terazosin Therapy for Patients With Female Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Placebo Controlled Trial.
• Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial.
• Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity.
• Does sildenafil cause myocardial infarction or sudden cardiac death?
• Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States.
• Food restriction alters pramipexole-induced yawning, hypothermia, and locomotor activity in rats: Evidence for sensitization of dopamine D2 receptor-mediated effects.
• Discovery of a Novel Series of Biphenyl Benzoic Acid Derivatives as Potent and Selective Human beta3-Adrenergic Receptor Agonists with Good Oral Bioavailability. Part I.
• Efficient Gene Expression System Using the RTP801 Promoter in the Corpus Cavernosum of High-Cholesterol Diet-Induced Erectile Dysfunction Rats for Gene Therapy.
• Design, Synthesis, and SAR of New Pyrrole-Oxindole Progesterone Receptor Modulators Leading to 5-(7-Fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
• Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
• Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
• Therapeutic Response after First Month of Tadalafil Treatment Predicts 12 Months Treatment Continuation in Patients with Erectile Dysfunction: Results from the DETECT Study.
• The Use of Old and Recent DSM Definitions of Premature Ejaculation in Observational Studies: A Contribution to the Present Debate for a New Classification of PE in the DSM-V.
• Assessment of Sexual Health in Aging Men in Europe: Development and Validation of the European Male Ageing Study Sexual Function Questionnaire.
• The Functional and Structural Consequences of Cavernous Nerve Injury are Ameliorated by Sildenafil Citrate.
• Contractile Changes of the Clitoral Cavernous Smooth Muscle in Female Rabbits with Experimentally Induced Overactive Bladder.
• Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
• Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study.
• Diagnosis and treatment of female sexual dysfunction.
• Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1alpha as Possible Biomarkers for the Chronic Pelvic Pain Syndrome.
• Small conductance, Ca2+- activated K+ channel 2 (SK2) is the key functional component of SK channels in mouse urinary bladder.
• The vitamin D receptor agonist elocalcitol up-regulates L-type calcium channel activity in human and rat bladder.
• Antipsychotic-Like Properties of 5-alpha-Reductase Inhibitors.
• Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats.
• Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation.
• Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination.
• Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.
• The Effect of Erectile Function on the Use of Phosphodiesterase-5 Inhibitors After Radical Prostatectomy in Japanese and U.S. Men.
• Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.
• Duration of erectile dysfunction and its relationship to treatment seeking and satisfaction with treatment using PDE5 inhibitors.
• Effect of eviprostat on bladder overactivity in an experimental cystitis rat model.
• Tamsulosin Treatment of Chronic Non-bacterial Prostatitis.
• Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
• Dual Use of Bladder Anticholinergics and Cholinesterase Inhibitors: Long-Term Functional and Cognitive Outcomes.
• VB4-845: A conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.
• Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose.
• Synthesis and Pharmacological Evaluations of Sildenafil Analogues for Treatment of Erectile Dysfunction.
• Comparable Efficacy of Once-Daily Versus On-Demand Vardenafil in Men with Mild-to-Moderate Erectile Dysfunction: Findings of the RESTORE Study.
• Premature ejaculation: different pathophysiologies and etiologies determine its treatment.
• Novel 2-imidazoles as potent and selective alpha(1A) adrenoceptor partial agonists.
• Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.
• Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
• Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction.
• Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.
• The Effects of Citalopram and Fluoxetine on Sexual Behavior in Healthy Men: Evidence of Delayed Ejaculation and Unaffected Sexual Desire. A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Parallel Group Study.
• Sexual Satisfaction among Patients with Erectile Dysfunction Treated with Counseling, Sildenafil, or Both.
• Genital Responsiveness in Healthy Women With and Without Sexual Arousal Disorder.
• Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation.
• Effects of The {beta}3-adrenergic Receptor Agonist CL-316243 on Bladder Micturition Reflex in Spontaneously Hypertensive Rats.
• Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia.
• Characteristics and expectations of patients with erectile dysfunction: results of the SCORED study.
• Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
• Yohimbine enhances the effect of sildenafil on erectile process in rats.
• The Effect of 5 {alpha}-Reductase Inhibitors on Erectile Function.
• Effect of Caffeine on Erectile Function Via Up-Regulating Cavernous cGMP in Diabetic Rats.
• Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.
• Nicotinic Signaling Ameliorates Acute Bladder Inflammation Induced by Protamine Sulfate or Cyclophosphamide.
• Role of Spinal Cav2.2 and Cav2.1 Ion Channels in Bladder Nociception.